ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) has experienced a rise in its stock price by 11.58 compared to its previous closing price of 0.57. However, the company has seen a gain of 11.46% in its stock price over the last five trading days. businesswire.com reported 2025-06-05 that AUSTIN, Texas–(BUSINESS WIRE)—- $AMD #AI–ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowi.
Is It Worth Investing in ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) Right Now?
The 36-month beta value for IPA is also noteworthy at 0.22. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IPA is 21.62M, and at present, short sellers hold a 0.76% of that float. The average trading volume of IPA on June 05, 2025 was 972.18K shares.
IPA’s Market Performance
The stock of ImmunoPrecise Antibodies Ltd (IPA) has seen a 11.46% increase in the past week, with a 34.31% rise in the past month, and a 60.00% gain in the past quarter. The volatility ratio for the week is 1.38%, and the volatility levels for the past 30 days are at 4.15% for IPA. The simple moving average for the past 20 days is 22.74% for IPA’s stock, with a 28.61% simple moving average for the past 200 days.
Analysts’ Opinion of IPA
Many brokerage firms have already submitted their reports for IPA stocks, with H.C. Wainwright repeating the rating for IPA by listing it as a “Buy.” The predicted price for IPA in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on December 02, 2022 of the previous year 2022.
The Benchmark Company, on the other hand, stated in their research note that they expect to see IPA reach a price target of $12. The rating they have provided for IPA stocks is “Buy” according to the report published on October 25th, 2021.
IPA Trading at 38.44% from the 50-Day Moving Average
After a stumble in the market that brought IPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.74% of loss for the given period.
#####
#####
Stock Fundamentals for IPA
Current profitability levels for the company are sitting at:
- -0.55 for the present operating margin
- 0.51 for the gross margin
The net margin for ImmunoPrecise Antibodies Ltd stands at -1.92. The total capital return value is set at -0.36. Equity return is now at value -121.65, with -73.58 for asset returns.
Based on ImmunoPrecise Antibodies Ltd (IPA), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -0.6. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -20.5.
Currently, EBITDA for the company is -22.95 million with net debt to EBITDA at -0.0. When we switch over and look at the enterprise to sales, we see a ratio of 1.69. The receivables turnover for the company is 4.93for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.32.
Conclusion
In summary, ImmunoPrecise Antibodies Ltd (IPA) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
